Dr. Kessler, who led the agency’s efforts to regulate the tobacco industry in the 1990s, in the interview said he “can’t see how” Juul wins regulatory approval from the FDA.
All e-cigarettes currently on the market have to go through FDA review to stay on the market, and the deadline to submit applications is May 2020. Dr. Kessler said he wouldn’t bet on any e-cigarettes surviving the FDA review.
Juul has largely been blamed for fueling the outbreak of a mysterious vaping-related lung illness that the CDC named EVALI. Dr. Kessler said the company’s use of nicotine salts, which makes high concentrations of nicotine less harsh on the throat, made it easier for kids to get hooked on e-cigarettes. Nicotine salts also deliver a faster and more intense hit than freebase nicotine, which was used in e-cigarettes before Juul introduced the salts in 2015, according to CNBC.
Read the full article here.
More articles on population health:
AMA urges Facebook, Amazon and others to help combat illicit vaping sales
Surge of hepatitis A outbreaks linked to opioid epidemic
Stop using vape products containing THC, FDA warns
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
